Related Experiment Videos
Type III membranoproliferative glomerulonephritis: long-term clinical and morphologic evaluation
Abstract:
Seventeen patients with Type III membranoproliferative glomerulonephritis (MPGN) have been followed for more than two years; 16 were treated with alternate day prednisone. Clinical deterioration correlated with nephrotic syndrome (NS) at diagnosis: 3 of 7 patients with NS at diagnosis developed end-stage disease. Serial biopsies in the others showed progressive disease in one, improvement in one and no change in two. Of 10 patients without NS at diagnosis, 6 have improved clinically, 2 are unchanged and 2 are worse. In serial biopsies, 6 showed improved morphology and 4 were unchanged. The results indicate that Type III MPGN will stabilize or improve in most treated patients. The absence of ultrastructural transition of a Type III glomerular lesion to another type and the presence of distinctive immunofluorescent findings and complement abnormalities confirm that Type III is a unique form of MPGN.
Insights
Alternate day prednisone treatment stabilized or improved most patients with Type III membranoproliferative glomerulonephritis (MPGN). Patients without nephrotic syndrome (NS) at diagnosis showed better outcomes, indicating Type III MPGN is a distinct entity.
Area of Science:
- Nephrology
- Immunology
- Pathology
Background:
- Type III membranoproliferative glomerulonephritis (MPGN) is a distinct renal disease.
- Understanding its clinical course and response to treatment is crucial.
Purpose of the Study:
- To evaluate the long-term clinical and morphologic outcomes of Type III MPGN.
- To assess the efficacy of alternate-day prednisone treatment in Type III MPGN patients.
Main Methods:
- Retrospective follow-up of 17 patients with Type III MPGN over two years.
- 16 patients received alternate-day prednisone therapy.
- Clinical assessment and serial kidney biopsies were performed.
Main Results:
- Most patients (16/17) were treated with alternate-day prednisone.
- Patients without nephrotic syndrome (NS) at diagnosis showed higher rates of clinical improvement (6/10) and morphologic improvement (6/10).
- Patients with NS at diagnosis had a higher risk of progression to end-stage disease (3/7).
Conclusions:
- Type III MPGN demonstrates a unique clinical course and distinct immunofluorescence findings.
- Alternate-day prednisone appears to stabilize or improve the condition in a majority of treated patients.
- Absence of ultrastructural transition supports Type III MPGN as a unique entity.